

Global Pulmonary Hypertension Drug Market Research Report 2025(Status and Outlook)

<https://marketpublishers.com/r/G360215010A6EN.html>

Date: September 2025

Pages: 142

Price: US\$ 3,200.00 (Single User License)

ID: G360215010A6EN

Abstracts

Pulmonary hypertension (PH) drugs are pharmaceutical agents specifically designed to treat pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension, a rare and progressive disorder characterized by elevated blood pressure in the pulmonary arteries leading to right heart failure and high mortality. These therapeutics target distinct pathological pathways involved in the disease, including endothelin receptor antagonism, phosphodiesterase type 5 inhibition, prostacyclin pathway activation, and soluble guanylate cyclase stimulation, and are administered via various routes such as oral, inhaled, subcutaneous, or intravenous to improve exercise capacity, hemodynamics, and quality of life while delaying disease progression. The market is defined by a high unmet medical need, orphan drug status for many products, and a focus on combination therapies and novel mechanisms of action to address the complex pathophysiology of the condition.

The global Pulmonary Hypertension Drug market size was estimated at USD 1024.55 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 4.75% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Pulmonary Hypertension Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current

status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Pulmonary Hypertension Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Pulmonary Hypertension Drug market.

Global Pulmonary Hypertension Drug Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Sanofi
Vectura Group plc
Bayer AG
Ikaria Inc.
Proreo Pharma AG
Vicore Pharma AB
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals
Co. Ltd.

Market Segmentation (by Type)

IK-3001
Sildenafil Citrate IMD
IK-7002
Riociguat
SAR-407899
Others

Market Segmentation (by Application)

Clinic
Hospital
Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Pulmonary Hypertension Drug Market

Overview of the regional outlook of the Pulmonary Hypertension Drug Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pulmonary Hypertension Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future

development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Pulmonary Hypertension Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the

region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Pulmonary Hypertension Drug

1.2 Key Market Segments

1.2.1 Pulmonary Hypertension Drug Segment by Type

1.2.2 Pulmonary Hypertension Drug Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 PULMONARY HYPERTENSION DRUG MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Pulmonary Hypertension Drug Market Size (M USD) Estimates and Forecasts (2020-2033)

2.1.2 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts (2020-2033)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 PULMONARY HYPERTENSION DRUG MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global Pulmonary Hypertension Drug Product Life Cycle

3.3 Global Pulmonary Hypertension Drug Sales by Manufacturers (2020-2025)

3.4 Global Pulmonary Hypertension Drug Revenue Market Share by Manufacturers (2020-2025)

3.5 Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Pulmonary Hypertension Drug Average Price by Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 Pulmonary Hypertension Drug Market Competitive Situation and Trends

3.8.1 Pulmonary Hypertension Drug Market Concentration Rate

3.8.2 Global 5 and 10 Largest Pulmonary Hypertension Drug Players Market Share by

Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 PULMONARY HYPERTENSION DRUG INDUSTRY CHAIN ANALYSIS

4.1 Pulmonary Hypertension Drug Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PULMONARY HYPERTENSION DRUG MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Industry News

5.4.1 New Product Developments

5.4.2 Mergers & Acquisitions

5.4.3 Expansions

5.4.4 Collaboration/Supply Contracts

5.5 PEST Analysis

5.5.1 Industry Policies Analysis

5.5.2 Economic Environment Analysis

5.5.3 Social Environment Analysis

5.5.4 Technological Environment Analysis

5.6 Global Pulmonary Hypertension Drug Market Porter's Five Forces Analysis

5.6.1 Global Trade Frictions

5.6.2 U.S. Tariff Policy ? April 2025

5.6.3 Global Trade Frictions and Their Impacts to Pulmonary Hypertension Drug Market

5.7 ESG Ratings of Leading Companies

6 PULMONARY HYPERTENSION DRUG MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Pulmonary Hypertension Drug Sales Market Share by Type (2020-2025)

6.3 Global Pulmonary Hypertension Drug Market Size Market Share by Type (2020-2025)

6.4 Global Pulmonary Hypertension Drug Price by Type (2020-2025)

7 PULMONARY HYPERTENSION DRUG MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Pulmonary Hypertension Drug Market Sales by Application (2020-2025)

7.3 Global Pulmonary Hypertension Drug Market Size (M USD) by Application (2020-2025)

7.4 Global Pulmonary Hypertension Drug Sales Growth Rate by Application (2020-2025)

8 PULMONARY HYPERTENSION DRUG MARKET SALES BY REGION

8.1 Global Pulmonary Hypertension Drug Sales by Region

8.1.1 Global Pulmonary Hypertension Drug Sales by Region

8.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Region

8.2 Global Pulmonary Hypertension Drug Market Size by Region

8.2.1 Global Pulmonary Hypertension Drug Market Size by Region

8.2.2 Global Pulmonary Hypertension Drug Market Size Market Share by Region

8.3 North America

8.3.1 North America Pulmonary Hypertension Drug Sales by Country

8.3.2 North America Pulmonary Hypertension Drug Market Size by Country

8.3.3 U.S. Market Overview

8.3.4 Canada Market Overview

8.3.5 Mexico Market Overview

8.4 Europe

8.4.1 Europe Pulmonary Hypertension Drug Sales by Country

8.4.2 Europe Pulmonary Hypertension Drug Market Size by Country

8.4.3 Germany Market Overview

8.4.4 France Market Overview

8.4.5 U.K. Market Overview

8.4.6 Italy Market Overview

8.4.7 Spain Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Pulmonary Hypertension Drug Sales by Region

8.5.2 Asia Pacific Pulmonary Hypertension Drug Market Size by Region

8.5.3 China Market Overview

8.5.4 Japan Market Overview

- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
 - 8.6.1 South America Pulmonary Hypertension Drug Sales by Country
 - 8.6.2 South America Pulmonary Hypertension Drug Market Size by Country
 - 8.6.3 Brazil Market Overview
 - 8.6.4 Argentina Market Overview
 - 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
 - 8.7.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Region
 - 8.7.2 Middle East and Africa Pulmonary Hypertension Drug Market Size by Region
 - 8.7.3 Saudi Arabia Market Overview
 - 8.7.4 UAE Market Overview
 - 8.7.5 Egypt Market Overview
 - 8.7.6 Nigeria Market Overview
 - 8.7.7 South Africa Market Overview

9 PULMONARY HYPERTENSION DRUG MARKET PRODUCTION BY REGION

- 9.1 Global Production of Pulmonary Hypertension Drug by Region(2020-2025)
- 9.2 Global Pulmonary Hypertension Drug Revenue Market Share by Region (2020-2025)
- 9.3 Global Pulmonary Hypertension Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Pulmonary Hypertension Drug Production
 - 9.4.1 North America Pulmonary Hypertension Drug Production Growth Rate (2020-2025)
 - 9.4.2 North America Pulmonary Hypertension Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Pulmonary Hypertension Drug Production
 - 9.5.1 Europe Pulmonary Hypertension Drug Production Growth Rate (2020-2025)
 - 9.5.2 Europe Pulmonary Hypertension Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Pulmonary Hypertension Drug Production (2020-2025)
 - 9.6.1 Japan Pulmonary Hypertension Drug Production Growth Rate (2020-2025)
 - 9.6.2 Japan Pulmonary Hypertension Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Pulmonary Hypertension Drug Production (2020-2025)

- 9.7.1 China Pulmonary Hypertension Drug Production Growth Rate (2020-2025)
- 9.7.2 China Pulmonary Hypertension Drug Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Sanofi

- 10.1.1 Sanofi Basic Information
- 10.1.2 Sanofi Pulmonary Hypertension Drug Product Overview
- 10.1.3 Sanofi Pulmonary Hypertension Drug Product Market Performance
- 10.1.4 Sanofi Business Overview
- 10.1.5 Sanofi SWOT Analysis
- 10.1.6 Sanofi Recent Developments

10.2 Vectura Group plc

- 10.2.1 Vectura Group plc Basic Information
- 10.2.2 Vectura Group plc Pulmonary Hypertension Drug Product Overview
- 10.2.3 Vectura Group plc Pulmonary Hypertension Drug Product Market Performance
- 10.2.4 Vectura Group plc Business Overview
- 10.2.5 Vectura Group plc SWOT Analysis
- 10.2.6 Vectura Group plc Recent Developments

10.3 Bayer AG

- 10.3.1 Bayer AG Basic Information
- 10.3.2 Bayer AG Pulmonary Hypertension Drug Product Overview
- 10.3.3 Bayer AG Pulmonary Hypertension Drug Product Market Performance
- 10.3.4 Bayer AG Business Overview
- 10.3.5 Bayer AG SWOT Analysis
- 10.3.6 Bayer AG Recent Developments

10.4 Ikaria Inc.

- 10.4.1 Ikaria Inc. Basic Information
- 10.4.2 Ikaria Inc. Pulmonary Hypertension Drug Product Overview
- 10.4.3 Ikaria Inc. Pulmonary Hypertension Drug Product Market Performance
- 10.4.4 Ikaria Inc. Business Overview
- 10.4.5 Ikaria Inc. Recent Developments

10.5 Proreo Pharma AG

- 10.5.1 Proreo Pharma AG Basic Information
- 10.5.2 Proreo Pharma AG Pulmonary Hypertension Drug Product Overview
- 10.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Product Market Performance
- 10.5.4 Proreo Pharma AG Business Overview
- 10.5.5 Proreo Pharma AG Recent Developments

10.6 Vicore Pharma AB

10.6.1 Vicore Pharma AB Basic Information

10.6.2 Vicore Pharma AB Pulmonary Hypertension Drug Product Overview

10.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Product Market Performance

10.6.4 Vicore Pharma AB Business Overview

10.6.5 Vicore Pharma AB Recent Developments

10.7 Biolab Sanus Farmaceutica Ltda.

10.7.1 Biolab Sanus Farmaceutica Ltda. Basic Information

10.7.2 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Overview

10.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Market Performance

10.7.4 Biolab Sanus Farmaceutica Ltda. Business Overview

10.7.5 Biolab Sanus Farmaceutica Ltda. Recent Developments

10.8 Hanmi Pharmaceuticals

10.8.1 Hanmi Pharmaceuticals Basic Information

10.8.2 Hanmi Pharmaceuticals Pulmonary Hypertension Drug Product Overview

10.8.3 Hanmi Pharmaceuticals Pulmonary Hypertension Drug Product Market Performance

10.8.4 Hanmi Pharmaceuticals Business Overview

10.8.5 Hanmi Pharmaceuticals Recent Developments

10.9 Co. Ltd.

10.9.1 Co. Ltd. Basic Information

10.9.2 Co. Ltd. Pulmonary Hypertension Drug Product Overview

10.9.3 Co. Ltd. Pulmonary Hypertension Drug Product Market Performance

10.9.4 Co. Ltd. Business Overview

10.9.5 Co. Ltd. Recent Developments

11 PULMONARY HYPERTENSION DRUG MARKET FORECAST BY REGION

11.1 Global Pulmonary Hypertension Drug Market Size Forecast

11.2 Global Pulmonary Hypertension Drug Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Pulmonary Hypertension Drug Market Size Forecast by Country

11.2.3 Asia Pacific Pulmonary Hypertension Drug Market Size Forecast by Region

11.2.4 South America Pulmonary Hypertension Drug Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of Pulmonary Hypertension Drug by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

12.1 Global Pulmonary Hypertension Drug Market Forecast by Type (2026-2033)

12.1.1 Global Forecasted Sales of Pulmonary Hypertension Drug by Type (2026-2033)

12.1.2 Global Pulmonary Hypertension Drug Market Size Forecast by Type (2026-2033)

12.1.3 Global Forecasted Price of Pulmonary Hypertension Drug by Type (2026-2033)

12.2 Global Pulmonary Hypertension Drug Market Forecast by Application (2026-2033)

12.2.1 Global Pulmonary Hypertension Drug Sales (K MT) Forecast by Application

12.2.2 Global Pulmonary Hypertension Drug Market Size (M USD) Forecast by Application (2026-2033)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Pulmonary Hypertension Drug Market Size Comparison by Region (M USD)

Table 5. Global Pulmonary Hypertension Drug Sales (K MT) by Manufacturers
(2020-2025)

Table 6. Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers
(2020-2025)

Table 7. Global Pulmonary Hypertension Drug Revenue (M USD) by Manufacturers
(2020-2025)

Table 8. Global Pulmonary Hypertension Drug Revenue Share by Manufacturers
(2020-2025)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in
Pulmonary Hypertension Drug as of 2024)

Table 10. Global Market Pulmonary Hypertension Drug Average Price (USD/KG) of Key
Manufacturers (2020-2025)

Table 11. Manufacturers? Manufacturing Sites, Areas Served

Table 12. Manufacturers? Product Type

Table 13. Global Pulmonary Hypertension Drug Manufacturers Market Concentration
Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Market Overview of Key Raw Materials

Table 16. Midstream Market Analysis

Table 17. Downstream Customer Analysis

Table 18. Key Development Trends

Table 19. Driving Factors

Table 20. Pulmonary Hypertension Drug Market Challenges

Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026

Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027

Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026

Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading
Countries

Table 25. Global Pulmonary Hypertension Drug Sales by Type (K MT)

Table 26. Global Pulmonary Hypertension Drug Market Size by Type (M USD)

Table 27. Global Pulmonary Hypertension Drug Sales (K MT) by Type (2020-2025)

Table 28. Global Pulmonary Hypertension Drug Sales Market Share by Type (2020-2025)
Table 29. Global Pulmonary Hypertension Drug Market Size (M USD) by Type (2020-2025)
Table 30. Global Pulmonary Hypertension Drug Market Size Share by Type (2020-2025)
Table 31. Global Pulmonary Hypertension Drug Price (USD/KG) by Type (2020-2025)
Table 32. Global Pulmonary Hypertension Drug Sales (K MT) by Application
Table 33. Global Pulmonary Hypertension Drug Market Size by Application
Table 34. Global Pulmonary Hypertension Drug Sales by Application (2020-2025) & (K MT)
Table 35. Global Pulmonary Hypertension Drug Sales Market Share by Application (2020-2025)
Table 36. Global Pulmonary Hypertension Drug Market Size by Application (2020-2025) & (M USD)
Table 37. Global Pulmonary Hypertension Drug Market Share by Application (2020-2025)
Table 38. Global Pulmonary Hypertension Drug Sales Growth Rate by Application (2020-2025)
Table 39. Global Pulmonary Hypertension Drug Sales by Region (2020-2025) & (K MT)
Table 40. Global Pulmonary Hypertension Drug Sales Market Share by Region (2020-2025)
Table 41. Global Pulmonary Hypertension Drug Market Size by Region (2020-2025) & (M USD)
Table 42. Global Pulmonary Hypertension Drug Market Size Market Share by Region (2020-2025)
Table 43. North America Pulmonary Hypertension Drug Sales by Country (2020-2025) & (K MT)
Table 44. North America Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Pulmonary Hypertension Drug Sales by Country (2020-2025) & (K MT)
Table 46. Europe Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Pulmonary Hypertension Drug Market Size by Region (2020-2025) & (M USD)
Table 49. South America Pulmonary Hypertension Drug Sales by Country (2020-2025)

& (K MT)

Table 50. South America Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (M USD)

Table 51. Middle East and Africa Pulmonary Hypertension Drug Sales by Region (2020-2025) & (K MT)

Table 52. Middle East and Africa Pulmonary Hypertension Drug Market Size by Region (2020-2025) & (M USD)

Table 53. Global Pulmonary Hypertension Drug Production (K MT) by Region(2020-2025)

Table 54. Global Pulmonary Hypertension Drug Revenue (US\$ Million) by Region (2020-2025)

Table 55. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2020-2025)

Table 56. Global Pulmonary Hypertension Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 57. North America Pulmonary Hypertension Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. Europe Pulmonary Hypertension Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Japan Pulmonary Hypertension Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 60. China Pulmonary Hypertension Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 61. Sanofi Basic Information

Table 62. Sanofi Pulmonary Hypertension Drug Product Overview

Table 63. Sanofi Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 64. Sanofi Business Overview

Table 65. Sanofi SWOT Analysis

Table 66. Sanofi Recent Developments

Table 67. Vectura Group plc Basic Information

Table 68. Vectura Group plc Pulmonary Hypertension Drug Product Overview

Table 69. Vectura Group plc Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 70. Vectura Group plc Business Overview

Table 71. Vectura Group plc SWOT Analysis

Table 72. Vectura Group plc Recent Developments

Table 73. Bayer AG Basic Information

Table 74. Bayer AG Pulmonary Hypertension Drug Product Overview

Table 75. Bayer AG Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 76. Bayer AG Business Overview

Table 77. Bayer AG SWOT Analysis

Table 78. Bayer AG Recent Developments

Table 79. Ikaria Inc. Basic Information

Table 80. Ikaria Inc. Pulmonary Hypertension Drug Product Overview

Table 81. Ikaria Inc. Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 82. Ikaria Inc. Business Overview

Table 83. Ikaria Inc. Recent Developments

Table 84. Proreo Pharma AG Basic Information

Table 85. Proreo Pharma AG Pulmonary Hypertension Drug Product Overview

Table 86. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 87. Proreo Pharma AG Business Overview

Table 88. Proreo Pharma AG Recent Developments

Table 89. Vicore Pharma AB Basic Information

Table 90. Vicore Pharma AB Pulmonary Hypertension Drug Product Overview

Table 91. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 92. Vicore Pharma AB Business Overview

Table 93. Vicore Pharma AB Recent Developments

Table 94. Biolab Sanus Farmaceutica Ltda. Basic Information

Table 95. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Overview

Table 96. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 97. Biolab Sanus Farmaceutica Ltda. Business Overview

Table 98. Biolab Sanus Farmaceutica Ltda. Recent Developments

Table 99. Hanmi Pharmaceuticals Basic Information

Table 100. Hanmi Pharmaceuticals Pulmonary Hypertension Drug Product Overview

Table 101. Hanmi Pharmaceuticals Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 102. Hanmi Pharmaceuticals Business Overview

Table 103. Hanmi Pharmaceuticals Recent Developments

Table 104. Co. Ltd. Basic Information

Table 105. Co. Ltd. Pulmonary Hypertension Drug Product Overview

Table 106. Co. Ltd. Pulmonary Hypertension Drug Sales (K MT), Revenue (M USD),

Price (USD/KG) and Gross Margin (2020-2025)

Table 107. Co. Ltd. Business Overview

Table 108. Co. Ltd. Recent Developments

Table 109. Global Pulmonary Hypertension Drug Sales Forecast by Region
(2026-2033) & (K MT)

Table 110. Global Pulmonary Hypertension Drug Market Size Forecast by Region
(2026-2033) & (M USD)

Table 111. North America Pulmonary Hypertension Drug Sales Forecast by Country
(2026-2033) & (K MT)

Table 112. North America Pulmonary Hypertension Drug Market Size Forecast by
Country (2026-2033) & (M USD)

Table 113. Europe Pulmonary Hypertension Drug Sales Forecast by Country
(2026-2033) & (K MT)

Table 114. Europe Pulmonary Hypertension Drug Market Size Forecast by Country
(2026-2033) & (M USD)

Table 115. Asia Pacific Pulmonary Hypertension Drug Sales Forecast by Region
(2026-2033) & (K MT)

Table 116. Asia Pacific Pulmonary Hypertension Drug Market Size Forecast by Region
(2026-2033) & (M USD)

Table 117. South America Pulmonary Hypertension Drug Sales Forecast by Country
(2026-2033) & (K MT)

Table 118. South America Pulmonary Hypertension Drug Market Size Forecast by
Country (2026-2033) & (M USD)

Table 119. Middle East and Africa Pulmonary Hypertension Drug Sales Forecast by
Country (2026-2033) & (Units)

Table 120. Middle East and Africa Pulmonary Hypertension Drug Market Size Forecast
by Country (2026-2033) & (M USD)

Table 121. Global Pulmonary Hypertension Drug Sales Forecast by Type (2026-2033)
& (K MT)

Table 122. Global Pulmonary Hypertension Drug Market Size Forecast by Type
(2026-2033) & (M USD)

Table 123. Global Pulmonary Hypertension Drug Price Forecast by Type (2026-2033) &
(USD/KG)

Table 124. Global Pulmonary Hypertension Drug Sales (K MT) Forecast by Application
(2026-2033)

Table 125. Global Pulmonary Hypertension Drug Market Size Forecast by Application
(2026-2033) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Pulmonary Hypertension Drug
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Pulmonary Hypertension Drug Market Size (M USD), 2024-2033
- Figure 5. Global Pulmonary Hypertension Drug Market Size (M USD) (2020-2033)
- Figure 6. Global Pulmonary Hypertension Drug Sales (K MT) & (2020-2033)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Pulmonary Hypertension Drug Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Pulmonary Hypertension Drug Product Life Cycle
- Figure 13. Pulmonary Hypertension Drug Sales Share by Manufacturers in 2024
- Figure 14. Global Pulmonary Hypertension Drug Revenue Share by Manufacturers in 2024
- Figure 15. Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
- Figure 16. Global Market Pulmonary Hypertension Drug Average Price (USD/KG) of Key Manufacturers in 2024
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Pulmonary Hypertension Drug Revenue in 2024
- Figure 18. Industry Chain Map of Pulmonary Hypertension Drug
- Figure 19. Global Pulmonary Hypertension Drug Market PEST Analysis
- Figure 20. Global Pulmonary Hypertension Drug Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Pulmonary Hypertension Drug Market Share by Type
- Figure 27. Sales Market Share of Pulmonary Hypertension Drug by Type (2020-2025)
- Figure 28. Sales Market Share of Pulmonary Hypertension Drug by Type in 2024
- Figure 29. Market Size Share of Pulmonary Hypertension Drug by Type (2020-2025)
- Figure 30. Market Size Share of Pulmonary Hypertension Drug by Type in 2024
- Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 32. Global Pulmonary Hypertension Drug Market Share by Application

Figure 33. Global Pulmonary Hypertension Drug Sales Market Share by Application (2020-2025)

Figure 34. Global Pulmonary Hypertension Drug Sales Market Share by Application in 2024

Figure 35. Global Pulmonary Hypertension Drug Market Share by Application (2020-2025)

Figure 36. Global Pulmonary Hypertension Drug Market Share by Application in 2024

Figure 37. Global Pulmonary Hypertension Drug Sales Growth Rate by Application (2020-2025)

Figure 38. Global Pulmonary Hypertension Drug Sales Market Share by Region (2020-2025)

Figure 39. Global Pulmonary Hypertension Drug Market Size Market Share by Region (2020-2025)

Figure 40. North America Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 41. North America Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 42. North America Pulmonary Hypertension Drug Sales Market Share by Country in 2024

Figure 43. North America Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 44. North America Pulmonary Hypertension Drug Market Size Market Share by Country in 2024

Figure 45. U.S. Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada Pulmonary Hypertension Drug Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada Pulmonary Hypertension Drug Market Size (M USD) and Growth Rate (2020-2025)

Figure 49. Mexico Pulmonary Hypertension Drug Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico Pulmonary Hypertension Drug Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe Pulmonary Hypertension Drug Sales Market Share by Country in

2024

Figure 53. Europe Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Pulmonary Hypertension Drug Market Size Market Share by Country in 2024

Figure 55. Germany Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Pulmonary Hypertension Drug Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Region in 2024

Figure 67. Asia Pacific Pulmonary Hypertension Drug Market Size Market Share by Region in 2024

Figure 68. China Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Pulmonary Hypertension Drug Sales and Growth Rate

(2020-2025) & (K MT)

Figure 73. South Korea Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America Pulmonary Hypertension Drug Sales and Growth Rate (K MT)

Figure 79. South America Pulmonary Hypertension Drug Sales Market Share by Country in 2024

Figure 80. South America Pulmonary Hypertension Drug Market Size and Growth Rate (M USD)

Figure 81. South America Pulmonary Hypertension Drug Market Size Market Share by Country in 2024

Figure 82. Brazil Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa Pulmonary Hypertension Drug Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Region in 2024

Figure 90. Middle East and Africa Pulmonary Hypertension Drug Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa Pulmonary Hypertension Drug Market Size Market Share by Region in 2024

Figure 92. Saudi Arabia Pulmonary Hypertension Drug Sales and Growth Rate

(2020-2025) & (K MT)

Figure 93. Saudi Arabia Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 95. UAE Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa Pulmonary Hypertension Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa Pulmonary Hypertension Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global Pulmonary Hypertension Drug Production Market Share by Region (2020-2025)

Figure 103. North America Pulmonary Hypertension Drug Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe Pulmonary Hypertension Drug Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan Pulmonary Hypertension Drug Production (K MT) Growth Rate (2020-2025)

Figure 106. China Pulmonary Hypertension Drug Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Pulmonary Hypertension Drug Sales Forecast by Volume (2020-2033) & (K MT)

Figure 108. Global Pulmonary Hypertension Drug Market Size Forecast by Value (2020-2033) & (M USD)

Figure 109. Global Pulmonary Hypertension Drug Sales Market Share Forecast by Type (2026-2033)

Figure 110. Global Pulmonary Hypertension Drug Market Share Forecast by Type (2026-2033)

Figure 111. Global Pulmonary Hypertension Drug Sales Forecast by Application (2026-2033)

Figure 112. Global Pulmonary Hypertension Drug Market Share Forecast by Application (2026-2033)

I would like to order

Product name: Global Pulmonary Hypertension Drug Market Research Report 2025(Status and Outlook)

Product link: <https://marketpublishers.com/r/G360215010A6EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G360215010A6EN.html>